Companies: 10,795·Total market cap: $144.5T
Bicycle Therapeutics plc

Bicycle Therapeutics plc

BCYCNASDAQHealthcare● Active
$4.11
$-0.09(-2.14%)
Market Cap$285211539
P/E Ratio—
52W High$9.36
52W Low$4.09
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Bicycle Therapeutics plc (BCYC) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BCYC · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.15bcyc eps ttm · bcyc earnings per shareEarnings history
PE Ratio (TTM)—bcyc pe ratio ttm · bcyc price to earningsPE Ratio deep dive
Revenue (TTM)$63.5Mbcyc revenue ttm · bcyc annual revenueFull revenue history
Dividend YieldNo Dividenddoes bcyc pay dividends · bcyc dividend yieldDividend history
Shares Outstanding69.3Mbcyc shares outstanding · bcyc floatShares outstanding history
Next EarningsAug 14, 2026Est.bcyc earnings date · bcyc next earningsEarnings history

Explore Bicycle Therapeutics plc Data

bcyc stock data · financials
Market Cap$285.2Mbcyc market cap · bcyc valuation
Analyst Forecast$11 · Buy
DividendsNo Dividenddoes bicycle therapeutics plc pay dividends · bcyc dividend yield
Revenue$72.6M+105.77%bicycle therapeutics plc annual revenue · bcyc revenue
EarningsEPS $-3.16-8.59%bcyc earnings · bcyc eps
PE Ratio—bcyc pe ratio · bcyc price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$72.6M▲ +105.77% YoY
202320242025
bicycle therapeutics plc revenue · bcyc revenue 2025
FY 2025Net Income-$219.0M▼ 29.54% YoY
202320242025
bicycle therapeutics plc net income · bcyc profit 2025
FY 2025EPS$-3.16▼ 8.59% YoY
202320242025
bcyc eps · bicycle therapeutics plc earnings per share 2025
TTM:Revenue: $63.5MNet Income: -$219.0MEPS: $-3.15View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy21 analystsis bcyc a buy · bcyc analyst rating
Strong Buy
0
Buy
17
Hold
4
Sell
0
Strong Sell
0
12-Month Price Target
$8.00Low
$4.11Current
$10.67Avg Target159.61% upside
$12.00High
bcyc price target · bcyc 12 month forecast

Total: 21 · Buy rate: 81.0%

The BCYC analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $10.67, representing +159.61% upside from the current price of $4.11.

Stock Performance

Full History
1D-1.64%
1W-2.33%
1M-12.68%
3M-19.23%
YTD-40.68%
1Y-50.82%
5Y-86.05%

About Bicycle Therapeutics plc

CEOKevin Lee
IPO DateMay 23, 2019
Employees305
CountryGB
Websitebicycletherapeutics.com

Bicycle Therapeutics plc founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently…

BiotechnologyHealthcareNASDAQADRGB

what is bicycle therapeutics plc · bcyc stock overview · bicycle therapeutics plc company profile · who is bicycle therapeutics plc ceo · bcyc NASDAQ · bicycle therapeutics plc headquarters · bicycle therapeutics plc business segments

About Stock Overview & Key Data

Bicycle Therapeutics plc (BCYC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 23, 2019. As of the latest trading session, BCYC stock price is $4.11, with a market capitalization of $285.2M. The stock has returned -50.82% over the past 12 months and -40.68% year-to-date.

According to 21 Wall Street analysts, the consensus rating for Bicycle Therapeutics plc stock is Buy, with an average 12-month price target of $10.67. In fiscal year 2025, Bicycle Therapeutics plc reported revenue of $72.6M and net income of -$219.0M. For detailed data — including Bicycle Therapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Bicycle Therapeutics plc (BCYC) stock price is $4.11. The stock is traded on NASDAQ under the ticker symbol BCYC. The 52-week range is $4.09 – $9.36.

BCYC stock priceBCYC quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice